Title |
Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, October 2013
|
DOI | 10.2147/ndt.s52463 |
Pubmed ID | |
Authors |
Yakup Albayrak, Cüneyt Ünsal, Neslihan Albayrak, Murat Kuloglu, Kenji Hashimoto |
Abstract |
Second generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 31 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 16% |
Researcher | 4 | 13% |
Student > Bachelor | 3 | 9% |
Unspecified | 2 | 6% |
Student > Doctoral Student | 2 | 6% |
Other | 9 | 28% |
Unknown | 7 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 22% |
Psychology | 5 | 16% |
Unspecified | 2 | 6% |
Arts and Humanities | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Other | 4 | 13% |
Unknown | 11 | 34% |